1, 2025 from Wharton, S., Calanna, S., Davies, M., et al
Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity
Semaglutide Injectable 4 mg/mL Home Product Class GLP-1 Semaglutide Injectable 4 mg/mL Semaglutide Injectable 4 mg/mL Drug Information: This is a Compounded Drug For SQ / IM only Not For Resale, Rx Only General Information: Protect From Light Keep Refrigerated Categories: GLP-1, Vial Item added to cart View Cart Checkout
Boehringer Ingelheim describes it as a dual glucagon/GLP1 receptor agonist that has the potential to address obesity while also supporting liver function, a key regulator of metabolic health. The company links the waistcircumference reduction in SYNCHRONIZE1 to effects on visceral fat, noting that excess visceral fat, particularly abdominal, is a known contributor to metabolic dysfunction and closely connected to impaired liver function